BioCentury | May 26, 2020
Distillery Therapeutics

Blocking inhibitor of apoptosis proteins in liver cells to treat malaria

DISEASE CATEGORY: Infectious disease INDICATION: Malaria Targeting IAP, a family of apoptosis-blocking proteins that includes BIRC2 and BIRC3, could treat malaria by clearing liver infection. In mice infected with Plasmodium berghei sporozoites, the parasite stage...
BC Innovations | Sep 11, 2017
Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest combining DIABLO mimetics with an oncolytic vesicular stomatitis virus (VSV) could help treat rhabdomyosarcoma. In an orthotopic xenograft mouse model of the cancer, the DIABLO mimetic LCL161 plus an oncolytic...
BC Week In Review | Jul 21, 2017
Clinical News

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

Debiopharm Group (Lausanne, Switzerland) completed enrollment of 96 patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) in the Phase II portion of a double-blind, placebo-controlled, French and Swiss...
BC Week In Review | Jun 13, 2016
Clinical News

AT-406: Phase II started

Debiopharm began a double-blind Phase II trial of oral Debio 1143 plus carboplatin and paclitaxel. Debiopharm has exclusive, worldwide rights from Ascenta to develop and commercialize Debio 1143 (see BioCentury, Sept. 12, 2011). Ascenta Therapeutics...
BC Week In Review | Aug 4, 2014
Clinical News

AT-406: Phase I data

An open-label, U.S. Phase I trial in 29 AML patients showed that once-daily 100, 200, 300 or 400 mg oral Debio 1143 plus daunorubicin and cytarabine led to complete remission in 13 patients. Of those...
BC Week In Review | Jun 17, 2013
Clinical News

Debio 1143: Phase I started

Debiopharm began a Phase I trial to evaluate Debio 1143 plus carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), platinum-refractory ovarian cancer or basal-like/claudin-low triple negative breast cancer. Debiopharm has exclusive, worldwide...
BioCentury | Jul 23, 2012
Product Development

Debio's dual deal

Debiopharm Group has been stocking up its early stage cancer pipeline with assets it believes have best-in-class potential, the latest being a preclinical dual tyrosine kinase inhibitor from Ascepion Pharmaceuticals Inc. The deal is the...
BC Week In Review | Sep 12, 2011
Company News

Ascenta, Ascentage Pharma Group Corp., Debiopharm deal

Ascenta granted Debiopharm exclusive, worldwide rights to develop and commercialize AT-406 ( Debio 1143 ). Ascenta will complete two ongoing U.S. Phase I trials with the compound in acute myelogenous leukemia (AML) and in solid tumors...
BC Innovations | Apr 28, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); BIRC3 (cIAP2); x-linked inhibitor of apoptosis (XIAP) A study in mice identified bivalent inhibitors...
BC Week In Review | Dec 6, 2010
Company News

Ascenta, Ascentage Pharma Group Corp. deal

Ascenta granted Ascentage rights to develop and commercialize AT-101 and AT-406 in China and Taiwan. Ascentage also will have rights to AT-101 for all regions outside the U.S., Canada and Europe. Ascenta will receive an...
Items per page:
1 - 10 of 11